OKYO Pharma (NASDAQ:OKYO) Raised to “Strong-Buy” at Piper Sandler

OKYO Pharma (NASDAQ:OKYO) was upgraded by analysts at Piper Sandler to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities research analysts have also recently commented on OKYO. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Thursday, January 22nd. Finally, B. Riley Financial started coverage on shares of OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OKYO Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.33.

OKYO Pharma Trading Down 3.4%

OKYO opened at $1.70 on Friday. OKYO Pharma has a twelve month low of $1.03 and a twelve month high of $3.35. The company has a fifty day moving average of $2.11 and a 200-day moving average of $2.23.

OKYO Pharma (NASDAQ:OKYO) last issued its quarterly earnings results on Friday, January 30th. The company reported ($2.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($2.21). As a group, analysts forecast that OKYO Pharma will post -0.17 EPS for the current year.

Institutional Investors Weigh In On OKYO Pharma

Several hedge funds and other institutional investors have recently modified their holdings of OKYO. Citadel Advisors LLC acquired a new position in shares of OKYO Pharma during the third quarter worth approximately $31,000. Renaissance Technologies LLC increased its stake in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in OKYO Pharma during the fourth quarter worth $36,000. Institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.